Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 plus lenvatinib in advanced solid tumors
CTR20220650Phase 2Active
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rulonilimab, lenvatinib in Nonhematologic neoplasms, endometrial cancer (EC), Cervical Cancer (CC), non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC), sponsored by Shandong New Era Pharmaceutical. Started May 2022; status: active.
02
Drugs
rulonilimablenvatinib
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)Cervical Cancer (CC)non-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20220650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220650.